#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
A formal research collaboration between the University of the West Indies Faculty of Informatics and Computing (UWIFIC) and Antigua and Barbuda’s Medicinal Cannabis Authority has been established to advance cannabis research and development in the Caribbean region. This partnership aims to systematize scientific investigation of cannabis therapeutics while ensuring regulatory oversight, which is particularly relevant for clinicians seeking evidence-based guidance on cannabis use in populations with limited local research infrastructure. By formalizing research protocols and data collection, the collaboration can generate region-specific efficacy and safety data that may better reflect the genetic diversity and disease profiles of Caribbean populations. Such institutional partnerships strengthen the scientific foundation for cannabis medicine practice by creating standardized research frameworks that ultimately produce higher-quality evidence for clinical decision-making. Clinicians working with Caribbean patients or those interested in how regional research initiatives can improve cannabis medicine should monitor this partnership’s publications to access population-relevant therapeutic data.
“When research institutions and regulatory bodies actually collaborate like this, we start to get the clinical evidence we’ve been lacking for two decades, which means I can move from anecdotal observations to real data when counseling patients about what cannabis can and cannot do for their conditions.”
? While formal research partnerships between academic institutions and national cannabis authorities represent a promising step toward generating rigorous clinical evidence in regions with limited data, clinicians should remain cautious about translating emerging findings into practice recommendations without established safety and efficacy benchmarks. The Caribbean context presents both opportunities for studying cannabis in diverse populations underrepresented in cannabis research and challenges around standardization of plant material, dosing, and outcome measurement that can complicate evidence synthesis. Confounders such as variable regulatory oversight, differences in cannabinoid profiles between cultivars, and the potential influence of political or economic incentives on research priorities warrant careful critical appraisal of any resulting publications. As more jurisdictions formalize cannabis research infrastructure, clinicians should maintain their usual rigor in evaluating cannabis-related claims, consulting systematic reviews and meta-analyses rather than isolated studies, and acknowledging that clinical evidence for specific cannabis indications remains limited for most conditions. When patients inquire
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
